LGC Acquires Bioanalytical Sciences from Quotient Bioresearch

Quotient’s Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals, and microbiological testing to customers in the pharmaceutical and biotechnology sectors. Upon acquisition, the Bioanalytical division will form part of LGC’s Health Sciences division and will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector, including bioanalysis, materials science, and reference materials, among others. Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences. This will enable clients to continue to benefit from the early development services offered by the Quotient group, including clinical trials, metabolism, and radiolabelling. For the time being, the Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership. The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science.

“We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology, and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities, and knowledgeable people,” said Jeremy Cook, managing director of LGC’s Health Sciences. Dr. Steve Pleasance, managing director of Quotient Bioanalytical Sciences said, “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”

Related Links:
LGC
Quotient Bioresearch